PA5-50959

antibody from Invitrogen Antibodies

Targeting: RIMKLB FAM80B, KIAA1238, NAAGS, NAAGS-I

Western blot (Supportive data in Antibodypedia)

Other assay (Supportive data in Antibodypedia)

Antibody Data

Product number

PA5-50959

Provider

Invitrogen Antibodies

Product name

RIMKLB Polyclonal Antibody

Antibody type

Polyclonal

Antigen

Synthetic peptide

Description

RIMKLB Polyclonal Antibody detects endogenous levels of RIMKLB protein.

Reactivity

Human, Mouse, Rat

Host

Rabbit

Isotype

IgG

Vial size

100 µL

Concentration

1 mg/mL

Storage

-20° C, Avoid Freeze/Thaw Cycles

References

Submitted references

Increasing Aspartoacylase in the Central Amygdala: The Common Mechanism of Gastroprotective Effects of Monoamine-Based Antidepressants Against Stress.

Yao K, Cao L, Ding H, Gao Y, Li T, Wang G, Zhang J
Frontiers in pharmacology 2022;13:823291

Western blot

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Western blot analysis of RIMKLB in HepG2 cells. Samples were probed using RIMKLB Polyclonal Antibody (Product # PA5-50959).

Other assay

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

FIGURE 3 Effect of pretreatment with duloxetine on NAA-related enzyme expression in CeA in rats exposed to 6 h/3 h/0.5 h of WIRS. (A) Representative immunoblots of ASPA/GCP II/GCP III/NAAGSI/Nat8l performed in CeA lysates. Western blotting showed that duloxetine pretreatment had no effect on the expression level of these enzymes in CeA after 6 h of WIRS ( n = 5 in control, 5 mg/kg duloxetine and 20 mg/kg duloxetine group, n = 6 in 0 mg/kg duloxetine group). (B) WIRS for 3 h decreased the expression of GCP II and Nat8l in CeA, and duloxetine did not modulate the expression of these two enzymes ( n = 5 per group), while pretreatment with 20 mg/kg duloxetine increased NAAGSI and slightly increased GCP III expression in CeA exposed to WIRS, which did not change by WIRS ( n = 6 per group). (C) WIRS for 0.5 h decreased the expression of APSA in CeA, and pretreatment with 20 mg/kg duloxetine reversed this decrement ( n = 6 per group). ASPA/GCP II/GCP III/NAAGSI/Nat8l was normalized to beta-actin. Values are expressed as means +- SEM. * p < 0.05, ** p < 0.01,*** p < 0.001, compared with control group, compared with control group, # p < 0.05, compared with WIRS + vehicle group.